All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
3 warning events since 2017; the latest 2024-08-02.
From the record
Rapid Micro Biosystems, Inc.'s filings since 2017 show 3 warning events: a notice about its exchange listing (8-K item 3.01, 3 times, the latest 2024-08-02) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+15.9% a year over 6 filed years; profitable in 0 of 6.
From the record
Rapid Micro Biosystems, Inc.'s 6 filed years say what it did: revenue went from $16 million in fiscal 2020 to $34 million in fiscal 2025, up 15.9% a year; it rose in 4 of 5 years; the deepest fall was 26% from fiscal 2021 to fiscal 2022; net income was positive in 0 of 6 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 4.5/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Rapid Micro Biosystems, Inc.'s shareholder treatment is put at 4.5 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the bottom 45% of 21 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -142%: lost 142¢ per shareholder dollar. Leverage 56%: owes 56¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Rapid Micro Biosystems, Inc. lost about 142 cents for every dollar of shareholders' money. Leverage: it owed about 56 cents per dollar of assets, and net share issuance: its share count grew 2.5% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 50% of 21 in its family; net margin -140.3%.
From the record
Rapid Micro Biosystems, Inc.'s standing among 21 graded names in its industry family: revenue of $34 million in fiscal 2025 ranks in the bottom 31% by size; a net margin of -140.3% ranks in the bottom 26%; revenue growth of 25.1% a year over the last 3 filed years ranks in the top 7% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
top 38% of 21 in its family for leadership; chief executive since 2021.
From the record
Rapid Micro Biosystems, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Spignesi, Robert G. Jr. (PRESIDENT AND CEO, as filed), filing under that title since 2021-07-14, 5.3 years (top 45% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 5.3 years (top 48%); 3 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (top 23%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
bottom 47% of 21 in its family for room to expand.
From the record
Rapid Micro Biosystems, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $20 million against debt of $19 million leaves 1.9% of its assets as net cash, bottom 39% of its family; cash from operations less capital spending is -95% of revenue (bottom 26%); research spending of 40.5% of revenue (top 22%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
top 36% of 21 in its family for growth drivers.
From the record
Rapid Micro Biosystems, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 25.1% a year over the last three filed years against 15.9% over all 6, speeding up (top 2% of its family); the newest year grew 19.8% (top 12%); research spending grew 1.9% a year (top 42%); capital spending grew -49.8% a year (bottom 13%) (its annual reports). Rapid Micro Biosystems, Inc. reported 2 product lines in fiscal 2025: Product at $23 million (70%), Service at $10 million (30%); 2 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 39% of 20 in its family for expectations against reality.
From the record
Rapid Micro Biosystems, Inc.'s newest year against its own record: revenue of $34 million in fiscal 2025 came in 6.4% below the $36 million its prior three years' pace pointed to (bottom 38% of its family); net income of $47 million against a prior three-year average of $53 million (top 37%); a net margin of a loss larger than its revenue against losses larger than its revenue before (top 17%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made